## Scientific Literature [Real PubMed articles with PMIDs and links] 
1. The true burden of COPD in India is therefore likely to be much higher than the estimated 37 million and could be close to around 50 million. 
   - Source: [What is the true burden of chronic obstructive pulmonary disease?](https://pmc.ncbi.nlm.nih.gov/articles/PMC8614607/) (PMID: 33799156)

2. Economic burden of asthma in India estimated at $81.9 billion, with significant costs attributed to absenteeism and mortality.
   - Source: [Economic burden of asthma in India](https://pmc.ncbi.nlm.nih.gov/articles/PMC6034365/) (PMID: 30385871)

3. The prevalence of COPD has increased from 3.3% (28.1 million cases) in 1990 to 4.4% (55.3 million cases) in 2019.
   - Source: [Burden of COPD among population above 30 years in India](https://pmc.ncbi.nlm.nih.gov/articles/PMC7850165/) (PMID: 33294899)

4. High burden of chronic obstructive pulmonary disease with an estimated economic burden of rs. 35,000 crore in India.
   - Source: [Cost of Severe Chronic Obstructive Pulmonary Disease](https://annalsofglobalhealth.org/articles/10.5334/aogh.2423) (PMID: 31514967)

## Web Sources [Real URLs from Serper]
1. [COPD: The Silent Lung Killer on the Rise in India](https://www.indiapharmaoutlook.com/news/copd-the-silent-lung-killer-on-the-rise-in-india-nwid-4529.html) - Discusses the increasing cases of COPD linked to smoking and environmental factors.
   
2. [Using Drug Patents to Block Competitors: The Tactics and Consequences](https://www.drugpatentwatch.com/blog/using-drug-patents-to-block-competitors-the-tactics-and-consequences/?srsltid=AfmBOop4GO5HcPB20-3zvpxJBVPubt_izjXhKsC5Y7hRoVTFq4u8eDIk) - Outlines how patenting affects drug pricing and access in India.
   
3. [Prevalence, time trends and treatment practices of asthma in India](https://pmc.ncbi.nlm.nih.gov/articles/PMC9149387/) - Details asthma prevalence in India and treatment practices.
   
4. [COPD: Burden and Strategies to Mitigate](https://www.dovepress.com/sub-optimal-chronic-obstructive-pulmonary-disease-copd-management-in-i-peer-reviewed-fulltext-article-COPD) - Discusses management gaps in COPD treatment in India.

These references illustrate the burden of respiratory diseases like asthma and COPD in India, highlighting their significant economic and public health implications, alongside the complexities introduced by patent competition in treatment options.